OBJECTIVE: To investigate the features of adverse drug reactions(ADR) occurred in out hospital.METHODS: A total of 311 ADR cases collected in our hospital from Jan 1,2006 to Nov 20,2008 were analyzed statistically in respect of the number of case reports,source of reports,drug categories,routes of administration,distribution of western and Chinese medicines organs and systems involved and the clinical manifestations etc.RESULTS: 78.8% of the total 311 cases were reported by physicians and 18.0% by pharmacists;Of all the drugs involved in ADR,anti-infective drugs accounted for 36.90%,and 64.9% of the western medicines and 64.8% of the Chinese medicines were administered via intravenous drip.Lesions of skin and the appendants represented 30.53% of the total ADR.CONCLULSION: ADR monitoring and medication intervention should be further strengthened in our hospital to promote rational drug use.

Objective To evaluate the effects of ELISPOT (enzyme-link immunospot) test using different samples in diagnosing tuberculous pleurisy. Methods Using T-Spot-TB kit to detect interferon-γlevel in pleural effusion and periph?eral blood from 164 patients with tuberculous pleural effusion and 102 patients without tuberculous pleural effusion. Number of spot forming cells (SFCs) as well as the specificity and sensitivity of the tests were compared between these two methods (ELISPOT using leural effusion or peripheral blood). Results The area under the ROC curve was 0.947 in pleural effusion Elispot test while it was 0.905 in peripheral blood Elispot test. The sensitivity of pleural effusion ELISPOT test in diagnosis of tuberculous pleurisy (95.1%) was significantly higher than that of peripheral blood ELISPOT test (89.0%). What’s more, the specificity of pleural effusion ELISPOT test in diagnosis of tuberculous pleurisy (90.2%) was higher than that in diagno?sis of peripheral blood ELISPOT test (88.2%). Conclusion The pleural effusion ELISPOT test is more valuable than periph?eral blood ELISPOT in the diagnosis of tuberculous pleuritis.

Objective To explore the role of parecoxib in protection of learning and memory ablility in rats with global cerebral ischemia/reperfusion injury. Methods Male Wistar rats were randomly divided into a sham group (S group), a ischemia/reperfusion group (I/R group), and a ischemia/reperfusion with parecoxib group (I/R+PA group). Global cerebral ischemia was induced by Pulsinelli 4-vessel occlusion. 72 h after reperfusion, Morris water maze was used to assess spatial learning and memory ability for consecutive five days. The histological changes in the hippocampus were detected by Nissl staining. Results As compared with the I/R group, rats in S guoup and I/R+PA group had a significantly shortened escape latency (P<0.05), and had significantly longer dwelling time in the former platform quadrant and more frequent cross-platform movement in the Morris water maze test. Conclusions Parecoxib plays a role in protection of learning and memory ability in rats with global cerebral ischemia/reperfusion injury.

Objective:To construct tissue engineering small-caliber anti-calcifiction blood vessels with micron slow-release magnesium chloride.Methods:After decellularizing sheep carotid artery by combining Triton X-100+ deoxycholate sodium salt and DNA/RNA ribozyme, tissue engineering small-caliber vascular scaffold was made, HE staining of elastic fiber and collagen were carried out at the same time, and scanning electron microscope was used to observe the decellularization and the performance of vascular stent. The microemulsion anti-calcification slow-release microsphere particles loaded with magnesium chloride(MgCl 2) were prepared by double emulsion method, ultrasonic breaking, high speed stirring and evaporation method. Detected the particle size, encapsulation rate, drug loading(rate) of the sustained-release microspheres and measured the sustained-release curve. After the artificial small-caliber blood vessel was cross-linked with carbodiimide hydrochloride/succinic imine(EDC/NHS), freeze-drying technology was used to combine the micron slow-release microspheres loaded with MgCl 2 with the vascular scaffold. Observed the combination under the electron microscope, and tested the thickness and tensile strength of the specimen blood vessels. Results:After decellularization, the sheep carotid artery could remove all kinds of cells and maintain the original performance of the scaffold. The averaged particle size of micro-calcium-resistant slow-release microspheres loaded with MgCl 2 was(1.31±0.02)μm, which was relatively uniform. The encapsulation rate of microsphere particles was 82.79%, and the drug loading(rate) was 2.98%, which existed within 25 days slow release, the release rate reached 81.08%. The slow-release microsphere particles loaded with chlorinase could be effectively and tightly combined with small-caliber tissue engineering blood vessels. Conclusion:The slow-release microsphere particles loaded with magnesium chloride made of PLGA as a carrier have the effect of slow-release magnesium ions. It laid the foundation for the construction of anti-calcification tissue engineering small-caliber blood vessels.

Objective To compare the antiviral effects of lamivudine and entecavir for patients with chronic hepatitis B. Methods 60 CHB patients were divided into two groupslamivudine group(30 cases)and entecavir group(30 cases). Liver and kidney function,HBV DNA and HBV serum markers were examined regularly. And ALT normalization,un-detectable HBV DNA and their adverse reactions were observed at 12,24 and 48 weeks. Results There was no signifi-cant difference in ALT normalization,undetectable HBV DNA between lamivudine group and entecavir group although there were higher rates of entecavir group after treatment. However, there was a significant difference in reproduction number of HBV DNA between two groups after 24 weeks,and there were less reproduction numbers of HBV DNA of entecavir group. Two groups of patients had sustained response data. Adverse reactions did not occur during treatment. Conclusion Entecavir is more effective in inhibiting reproduction of HBV than that of lamivudine.

Objective To develop a simple,multi-dimensional self-screening questionnaire for som-atoform symptoms(SQSS). Methods Based on theoretical framework,the study developed the items of the questionnaire. The first draft of the questionnaire was screened through the expert evaluation method. Four groups of 359 subjects were selected to test the reliability and validity of questionnaire. Results The explor-atory factor analysis showed that the four factors(somatic symptoms,negative perception,illness behavior and social function) were extracted and the interpretable percentage of variance was 61. 165%. The correlation between the subscales and the total scales was 0. 740-0. 887,and the correlation coefficient between the sub-scales was 0. 503-0. 625. The Crobanch's α coefficient of the questionnaire was 0. 926,and the Spearman-Brown score of the questionnaire was 0. 868. The retest correlation coefficient of the total scale was 0. 876. A cutoff of 23 points in the SQSS was identified for screening somatoform disorders, and the sensitivity was 0. 880 and the specificity was 0. 606. Conclusion SQSS has good reliability and validity,and can be prelim-inarily used as a self-screening tool for patients with somatoform symptoms or disorders in clinical settings.

Attentional bias towards threat may be a key factor associated with development and maintaining symptoms of obsessive-compulsive disorder (OCD).Through the study of attentional bias feature in OCD would be helpful to understand the obsessive-compulsive symptoms and development.We use emotion Stroop task,dot-probe task and eye-tracking methodology in measure attentional bias of obsessive-compulsive disorder,found that OCD patients may performance attentional bias to the general threat stimulus and obsessive-compulsive symptoms related stimulus,and OCD patients may have attentional bias to those obsessivecompulsive symptoms related stimulus in specialty.At present,difficult to repeat studies and inconsistent results are the main problems,and the differences in experimental materials and samples may be the important factors that lead to those inconsistency results.

The application of diagnosis and treatment technology based on virtual reality (VR) in obsessive-compulsive disorder (OCD) has attracted more and more attention from researchers around the world. The preliminary exploration shows that it is a promising auxiliary evaluation and treatment method. From the perspective of effectiveness and suitability, this paper systematically reviewed the research status of the application of VR technology in OCD clinical symptom evaluation, cognitive function evaluation and clinical intervention, discussed the similarities and differences, advantages and limitations between traditional evaluation and treatment methods and VR-based diagnosis and treatment technology, and prospected the new trend of the application of VR technology in OCD diagnosis and treatment, and provided a reference for the introduction, development and application of VR technology in China to improve the effect of OCD diagnosis and treatment.

Objective:To investigate the neurobiochemical metabolites of caudate nucleus and thalamus in patients with obsessive-compulsive disorder and their relationship with obsessive-compulsive symptoms.Methods:From April 2019 to January 2022 in Beijing Anding Hospital, totally 25 untreated patients with obsessive-compulsive disorder were recruited, and 20 healthy controls matched with gender, age and educational background were recruited for the study.The maps of neurobiochemical metabolites of patients and normal controls were collected by hydrogen proton magnetic resonance spectroscopy.With bilateral caudate nucleus and thalamus as brain regions of interest.The relative concentrations of N-acetylaspartic acid (NAA), glutamic acid (Glu) and γ-aminobutyric acid (GABA) were fitted by LCModel software.At the same time, the clinical symptoms of patients were evaluated with Yale-Brown obsessive-compulsive scale (Y-BOCS) and Hamilton anxiety scale (HAMA). SPSS 20.0 software was used for statistical analysis.Independent double sample t-test was used to compare the differences of different nerve biochemical metabolite concentrations between patients with obsessive-compulsive disorders and healthy controls.Pearson correlation analysis was used to explore the correlation between biochemical metabolite concentrations and clinical symptoms. Results:The Glu concentration in the left thalamus of patients with obsessive-compulsive disorder (3.97±0.41) was higher than that of the control group (3.66±0.55)( t=-2.11, P<0.05), while the NAA concentration was (4.87±0.47)lower than that of the control group (5.15±0.44)( t=2.05, P<0.05). The GABA concentrations in the right caudate nucleus (0.50±0.18) and thalamus (0.80±0.19) were lower than those in the control group ((0.63±0.23), (0.96±0.24))( t=2.08, 2.36, both P<0.05). Pearson correlation analysis showed that the Glu concentration in the left caudate nucleus of patients with obsessive-compulsive disorder was positively correlated with the total score of Y-BOCS( r=0.46, P<0.05). Spearman correlation analysis showed that Glu concentration in the right caudate nucleus was positively correlated with the total score of HAMA in patients with obsessive-compulsive disorder ( r=0.46, P<0.05). Conclusion:NAA, Glu and GABA metabolism in caudate nucleus and thalamus are abnormal in patients with obsessive-compulsive disorder, and Glu concentration is positively correlated with the severity of obsessive-compulsive and anxiety symptoms.

Objective:To further investigate the safety and efficacy of Belimumab in the treatment of patients with systemic lupus erythematosus (SLE).Methods:All SLE patients treated with Belimumab from May 1, 2020 to February 1, 2022 in Peking Union Medical College Hospital were retrospectively collected and analyzed. The clinical manifestations, the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) score, and laboratory test such as levels of anti-dsDNA antibody, the medication before and after Belimumab treatment, adverse events were collected. Normally distributed data were tested using the t-test, otherwise the Wilcoxon paired signed rank test was used. Results:A total of 81 patients were enrolled in this study. The use of belimumab could significantly decrease the SLEDAI-2000 score [10.00(7.75, 12.00) vs. 4.00(3.75, 6.00), Z=-5.38, P<0.001], ESR of SLE patients [19.50(12.75, 32.25) mm/1 h vs. 14.00(7.75, 20.25) mm/1 h, Z=-3.71, P=0.003], anti-dsDNA titer detected by CLIFT [300.00 (117.00, 864.00) vs. 183.00(100.00, 471.00), Z=-4.15, P=0.001], meanwhile, increase the complement C3 [0.78 (0.62, 0.97)g/L vs. 0.69 (0.55, 0.84)g/L, Z=-4.68, P<0.001], and the complement C4 [0.12 (0.08, 0.19)g/L vs. 0.10 (0.05, 0.14)g/L, Z=-4.78, P<0.001]. We also observed that with the use of Belimumab, the dosage of Glucocorticoids decreased significantly, which were [10.00(7.50, 22.50) mg vs. 7.50(5.00, 10.00) mg, Z=-4.90, P<0.001]. In addition, the antibody of IgG, IgA and IgM decreased significantly. Only one patient stopped the administration of Belimumab due to the low level of immunoglobulin. Conclusion:Belimumab can alleviate disease activity of patients with SLE and help in safely tapering the daily dose of glucocorticoid with good safety.